German Dementia Registry
DemReg
2 other identifiers
observational
5,000
1 country
24
Brief Summary
The German Dementia Registry (DEMREG) is a large-scale national prospective biomarker-based study for cognitive impairment and dementia, providing an integrated clinical research platform for research studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2022
Longer than P75 for all trials
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 16, 2022
CompletedFirst Submitted
Initial submission to the registry
February 4, 2026
CompletedFirst Posted
Study publicly available on registry
February 25, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2099
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2099
February 25, 2026
February 1, 2026
77.6 years
February 4, 2026
February 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary objective is the development of a registry to collect longitudinal data on patients with cognitive impairment and dementia with fluid biomarkers in Germany.
This will allow to evaluate the current diagnostic and treatment behavior and assess the natural history of a cohort of patients with SCD, MCI or early dementia with fluid and/or imaging biomarkers. The data collected on biomarkers and risk factors will help to differentiate e.g. patients with Alzheimer's dementia from patients with dementia of other etiology and to optimize diagnosis, management and care in a real-life environment.
This is an open-ended prospective registry. Data is collected during a baseline visit. Follow-up visits are conducted on an annual basis (1 year ±3 months) for as long as possible for each patient.
Interventions
This is an observational study; no treatments are carried out within the scope of the registry. The usual treatment/medication of patients is merely documented. Additionally, using a variety of questionnaires and tests, data is generated from participants in relation to early dementia.
Eligibility Criteria
This registry will be conducted in adult patients with a diagnosis of SCD, MCI or early dementia of different etiology and existing biomarkers such as cerebrospinal fluids (CSF) amyloid beta 1-42, amyloid beta 1-40, amyloid beta 1-42/amyloid beta 1-40 ratio, total tau and phosphorylated tau, amyloid or tau imaging.
You may qualify if:
- Ability of the participant and/or his/her legally authorized representative (e.g., spouse or legal guardian), as appropriate and applicable, to understand the purpose and risks of the register and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local privacy regulations.
- Participating patients must have a diagnosis of SCD, MCI or early dementia of different etiology (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy-Body Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Normal Pressure Hydrocephalus, Major Depression; Vascular Dementia; TDP-43 associated limbic encephalopathy (LATE), Mixed Dementia AD + VaD, Prion-Associated Dementia) together with biomarkers such as cerebrospinal fluids (CSF) amyloid beta 1-42, amyloid beta 1-40, amyloid beta 1-42/amyloid beta 1-40 ratio, total tau and phosphorylated tau, amyloid or tau imaging.
- At least 18 years of age.
- At least 18 years of age.
- Patient was included in the registry
- Family member is strongly involved to the patient's life according to the patient's statement
- Ability of the participant, as appropriate and applicable, to understand the purpose and risks of the register
You may not qualify if:
- Unwilling to provide informed consent.
- No available biomarkers such as cerebrospinal fluids (CSF) amyloid beta 1-42, amyloid beta 1-40, amyloid beta 1-42/amyloid beta 1-40 ratio, total tau and phosphorylated tau, amyloid or tau imaging.
- Unable or unwilling to provide informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- RWTH Aachen Universitylead
- Eisai GmbHcollaborator
- Lilly Deutschland GmbH Germanycollaborator
- Biogencollaborator
Study Sites (24)
Heidelberg University Hospital
Heidelberg, Baden-Wurttemberg, 69120, Germany
ZI Mannheim
Mannheim, Baden-Wurttemberg, 68159, Germany
University Hospital Tübingen
Tübingen, Baden-Wurttemberg, 72076, Germany
Ulm University Hospital
Ulm, Baden-Wurttemberg, 89070, Germany
Universitätsklinikum Erlangen
Erlangen, Bavaria, 91054, Germany
Klinikum Frankfurt (Oder)
Frankfurt (Oder), Brandenburg, 15236, Germany
Immanuel Klinik Rüdersdorf
Rüdersdorf, Brandenburg, 15562, Germany
Klinikum Bremen-Ost
Bremen, City state Bremen, 28325, Germany
Medical Center Hamburg-Eppendorf
Hamburg, Hamburg, 20251, Germany
Asklepios Klinik Nord
Hamburg, Hamburg, 22419, Germany
University Medical Center Göttingen
Göttingen, Lower Saxony, 37075, Germany
Greifswald University Medicine
Greifswald, Mecklenburg-Vorpommern, 17489, Germany
RWTH Aachen University Hospital
Aachen, North Rhine-Westphalia, 52074, Germany
University Hospital Cologne
Cologne, North Rhine-Westphalia, 50937, Germany
University Hospital Essen
Essen, North Rhine-Westphalia, 45147, Germany
Pfalzklinikum Klingenmünster
Klingenmünster, Rhineland-Palatinate, 76889, Germany
University Medical Center Mainz
Mainz, Rhineland-Palatinate, 55131, Germany
Saarland University Medical Center
Homburg, Saarland, 66421, Germany
University of Leipzig Medical Center
Leipzig, Saxony, 04103, Germany
Madical Faculty University Hospital Magdeburg
Magdeburg, Saxony-Anhalt, 39120, Germany
University Hospital Schleswig-Holstein
Kiel, Schleswig-Holstein, 24105, Germany
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Charité Campus Benjamin Franklin
Berlin, State of Berlin, 12203, Germany
University Hospital Jena
Jena, Thuringia, 07747, Germany
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jörg B. Schulz, Prof. Dr.
Department of Neurology, RWTH Aachen University Hospital
Central Study Contacts
Prof. Dr. Kathrin Reetz, MD
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 20 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr. Jörg B. Schulz, MD, Head of the Department of Neurology at the University Hospital Aachen and Project Manager
Study Record Dates
First Submitted
February 4, 2026
First Posted
February 25, 2026
Study Start
May 16, 2022
Primary Completion (Estimated)
December 1, 2099
Study Completion (Estimated)
December 1, 2099
Last Updated
February 25, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
Requests for data are deliberated in the Advisory Committee. If the outcome of the deliberation is positive, the data is passed on to the researchers in pseudonymised form. If the request comes from a commercial partner and the outcome of the deliberation is positive, the data is made available in anonymised form.